Zheng Quan Shi Bao Wang·2025-10-31 00:01Core Viewpoint - Small nucleic acid drugs are expected to become the third major category of drugs following small molecules and antibody drugs due to their ability to target traditionally undruggable targets and their long-lasting effects [1] Industry Developments - The breakthrough of GalNAc technology in 2014 established a successful paradigm for liver-targeted delivery, significantly activating industry development [1] - The global small nucleic acid drug industry is currently achieving commercial profitability, breakthroughs in indications, advancements in extrahepatic delivery, and dual-target breakthroughs [1] Competitive Landscape - Chinese companies are advancing alongside the global industry, demonstrating strong global competitiveness in the small nucleic acid drug sector [1]